Lugano (ots) - Faced with an uncertain economic environment, driven by a restrictive monetary policy and declining interest rates, the Cornèr Group maintained a stable growth trajectory thanks to its prudent philosophy and solid equity position, with capital resources rising to CHF 1,223 million (+5.9 %). The 73rd financial year closed with a balance sheet ...
Lugano/Zurich (ots) - Cornèr Group, Europe's first banking group, has launched Visa Commercial Pay (VCP) for mobile devices. This innovative solution allows companies to use virtual cards not only online, but also on smartphones and smartwatches. The ...
Lugano (ots) - Faced with an uncertain geopolitical and economic situation, Cornèr Group's prudent policy and long-held pragmatic approach have once again proven to be winning qualities. Cornèr Group's 72nd financial year closed with revenues reaching CHF 506 million (+16 %) and a net profit of CHF 74.9 million (+41 %). This result allows the Group to further strengthen its capital solidity with its capital ...
Lugano (ots) - Following a highly turbulent year, which saw the outbreak of the war in Ukraine and abrupt interest rate rises by the main central banks around the world, the Cornèr Group has now posted good results in its 71st Annual Report. Revenues increased to CHF 436 million, whilst the net profit rose to CHF 53.2 million, representing a strong increase compared to the previous year (CHF 22.7 million). ...
Lugano/Zurich (ots) - Starting from Switzerland, Cornèr Group introduces Visa Commercial Pay (VCP), supporting companies to quickly digitize B2B payments. The increasing pace of digitalisation in business processes creates new demands for payment capabilities of companies. A comprehensivesolution by ...
Lugano, Switzerland (ots/PRNewswire) - Temera, Luxochain and Polygon are pleased to announce their role as partners for the launch project of the new model Octo Finissimo Ultra, available in a limited edition of only 10 pieces. Bulgari with this initiative masters again its leadership as innovator in the hard luxury ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, has promoted an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. Lugano is increasingly a Blockchain & Crypto-Friendly City. After the launch at the ...
Lugano, Switzerland (ots/PRNewswire) - From 15-21 November Lugano Living Lab, the digital innovation laboratory of the City of Lugano, promotes an unprecedented exhibition that explores the fascinating world of NFT and Crypto Art with an exhibition, events and dedicated workshops. An unmissable opportunity to look into this new sector of digital art, discover ...
European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO)
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care, calling attention to the evolving and growing gap between the needs of cancer patients and the actual provision of patient-centred care. "New studies show that there may be a gap between what doctors think is important for patients, and what patients really need. With this position ...
European Society for Medical Oncology (ESMO)
Lugano, Switzerland and San Diego (ots/PRNewswire) - Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016 Global Phase 3 study site recruitment is ongoing Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, ...
Lugano, Switzerland and San Diego (ots/PRNewswire) - Data to be presented on December 3, 2016; Abstract now available online Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel ...
Lugano, Switzerland (ots/PRNewswire) - ~ Helsinn Group creates new investment fund in 40th anniversary year ~ ~ The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need ~ Helsinn, the Swiss Pharmaceutical Group focused on building quality cancer care, today introduces Helsinn Investment Fund S.A. ("the Fund"), a fund focused on early-stage investment opportunities in ...
Lugano, Switzerland (ots/PRNewswire) - ~ 40 years helping patients achieve a better quality of life ~ Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, is delighted to launch its 40th anniversary celebrations in San Francisco, US, at the time of the JP Morgan 34th Annual Healthcare Conference. Helsinn believes its core values of respect, integrity and quality have underpinned four decades of ...
European Society for Medical Oncology (ESMO)
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
Lugano, Switzerland (ots) - Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer ...
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
European Society for Medical Oncology (ESMO)
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...